Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Su

Showing results (891-900 of 1,172) with videos related to

Pageof 118
Sort By:
European Journal of Medicinal Chemistry|February 21, 2018
Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapyChuantao Zha, Wenjia Deng, Yan Fu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Basic Science and PathogenesisChristopher T Brown, Jessica Enos, Carolyn Langlois, et al.
Retina (Philadelphia, Pa.)|February 18, 2025
INCIDENCE AND RISK FACTORS FOR PROGRESSION OF PACHYCHOROID DISEASE SPECTRUMAngie Hon Chi Fong, Jinzhi Zhao, Wendy Meihua Wong, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2024
Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53Brendan L C Kinney, Sreenivasulu Gunti, Vikash Kansal, et al.
Expert Opinion on Drug Safety|April 22, 2024
Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysisQin-Yi Su, Liu Yang, Ting-Yu Cao, et al.
Acta Pharmacologica Sinica|September 15, 2017
SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer modelsXi-Fei Jiang, Yang Dai, Xia Peng, et al.
Scientific Reports|June 9, 2021
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790MYen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, et al.
Advances in Therapy|August 12, 2022
Levels of Peripheral Th17 Cells and Th17-Related Cytokines in Patients with Ankylosing Spondylitis: A Meta-analysisQin-Yi Su, Jing-Wen Zheng, Jing-Yuan Yang, et al.
Targeted Oncology|April 23, 2022
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in TaiwanYen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, et al.
Journal of Alzheimer'S Disease : JAD|December 20, 2021
Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry BiomarkerGang Wang, Wenju Zhou, Deping Kong, et al.
Pageof 118

Showing results (891-900 of 1,172) with videos related to

Sort By:
Pageof 118
European Journal of Medicinal Chemistry|February 21, 2018
Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapyChuantao Zha, Wenjia Deng, Yan Fu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Basic Science and PathogenesisChristopher T Brown, Jessica Enos, Carolyn Langlois, et al.
Retina (Philadelphia, Pa.)|February 18, 2025
INCIDENCE AND RISK FACTORS FOR PROGRESSION OF PACHYCHOROID DISEASE SPECTRUMAngie Hon Chi Fong, Jinzhi Zhao, Wendy Meihua Wong, et al.
Cancer Immunology, Immunotherapy : CII|January 17, 2024
Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53Brendan L C Kinney, Sreenivasulu Gunti, Vikash Kansal, et al.
Expert Opinion on Drug Safety|April 22, 2024
Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysisQin-Yi Su, Liu Yang, Ting-Yu Cao, et al.
Acta Pharmacologica Sinica|September 15, 2017
SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer modelsXi-Fei Jiang, Yang Dai, Xia Peng, et al.
Scientific Reports|June 9, 2021
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790MYen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, et al.
Advances in Therapy|August 12, 2022
Levels of Peripheral Th17 Cells and Th17-Related Cytokines in Patients with Ankylosing Spondylitis: A Meta-analysisQin-Yi Su, Jing-Wen Zheng, Jing-Yuan Yang, et al.
Targeted Oncology|April 23, 2022
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in TaiwanYen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, et al.
Journal of Alzheimer'S Disease : JAD|December 20, 2021
Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry BiomarkerGang Wang, Wenju Zhou, Deping Kong, et al.
Pageof 118